Get the Stockscreener App
26.62
1.66%
-0.45
After Hours:
26.62
Kodiak Sciences Inc stock is traded at $26.62, with a volume of 797.29K.
It is down -1.66% in the last 24 hours and up +1.84% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$27.07
Open:
$26.75
24h Volume:
797.29K
Relative Volume:
0.87
Market Cap:
$1.63B
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-7.0798
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-4.79%
1M Performance:
+1.84%
6M Performance:
+582.56%
1Y Performance:
+189.35%
1-Day Range:
$25.79
$27.03
1-Week Range:
$23.92
$28.23
52-Week Range:
$1.92
$31.18
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
26.62 | 1.65B | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
How analysts rate Kodiak Sciences Inc. stock todayJuly 2025 Action & High Conviction Investment Ideas - ulpravda.ru
Is Kodiak Sciences Inc. stock safe for conservative investorsWatch List & AI Powered Trade Plan Recommendations - ulpravda.ru
Can Kodiak Sciences Inc. stock weather global recessionJuly 2025 Institutional & Fast Moving Stock Trade Plans - ulpravda.ru
Will Kodiak Sciences Inc. stock outperform value stocksTrade Entry Report & Fast Entry Momentum Alerts - ulpravda.ru
Is Kodiak Sciences Inc. (K27) stock inflation resilient2025 Stock Rankings & Momentum Based Trading Signals - ulpravda.ru
Why Kodiak Sciences Inc. stock is in analyst buy zoneJuly 2025 Price Swings & Stepwise Swing Trade Plans - ulpravda.ru
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
UBS Initiates Coverage of Kodiak Sciences (KOD) with Buy Recommendation - Nasdaq
KOD: UBS Initiates Coverage with 'Buy' Rating and $50 Price Targ - GuruFocus
UBS initiates Kodiak Sciences stock with Buy rating, $50 price target - Investing.com Australia
Kodiak Sciences launches public offering of 6 mln shares - MSN
Volume Recap: Why GeneDx Holdings Corp Equity Warrant stock is rated strong buy - moha.gov.vn
Will Kodiak Sciences Inc stock outperform value stocksProfit Target & Long Hold Capital Preservation Plans - moha.gov.vn
Is Kodiak Sciences Inc a good long term investmentInsider Selling Patterns & Low Entry Investment Ideas - earlytimes.in
Kodiak Sciences Inc Stock Analysis and ForecastPrice Action Trading & Exceptional Capital Investment - earlytimes.in
Kodiak Sciences (NASDAQ:KOD) Shares Down 5.8%Here's Why - MarketBeat
The Biggest IPO of the Year Prompts Huge Insider Buy - AOL.com
Investors Buy Big as Medline’s IPO Raises Over $6 Billion - cointurk finance
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 5.8%Here's Why - MarketBeat
Kodiak Sciences stock hits 52-week high at $29.52 By Investing.com - Investing.com Australia
Kodiak Sciences Stock Surge: An In-Depth Look - timothysykes.com
Kodiak Sciences (NASDAQ:KOD) Shares Up 6%Here's Why - MarketBeat
Kodiak Sciences stock hits 52-week high at $29.52 - Investing.com
Kodiak Sciences (NASDAQ:KOD) Hits New 52-Week HighWhat's Next? - MarketBeat
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Insider Buying Activity - MarketBeat
Kodiak Sciences Inc.(NasdaqGM: KOD) added to S&P Biotechnology Select Industry Index - marketscreener.com
Kodiak Sciences (KOD): Assessing Valuation After Its $160 Million Capital Raise for Late-Stage Pipeline - Sahm
Can Kodiak Sciences Inc. stock maintain operating marginsMarket Sentiment Summary & Stock Timing and Entry Methods - Улправда
Bros. Advisors Lp Baker Buys 2,608,696 Shares of Kodiak Sciences (NASDAQ:KOD) Stock - MarketBeat
Owner Baker Bros Advisors LP Buys 2,608,696 ($60M) Of Kodiak Sciences Inc [KOD] - TradingView — Track All Markets
Kodiak Sciences closes $184 million public offering of common stock By Investing.com - Investing.com Nigeria
Kodiak Sciences closes $184 million public offering of common stock - Investing.com
Retina biotech raises $184M in stock sale as late-stage drug trials loom - Stock Titan
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
Kodiak Sciences Raises Capital Through Completed Stock Offering - TipRanks
Kodiak Sciences (NASDAQ: KOD) completes $184M common stock sale - Stock Titan
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.4%Here's Why - MarketBeat
Kodiak Sciences raises capital through completed stock offering - MSN
[424B5] Kodiak Sciences Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Is Kodiak Sciences Inc. (K27) stock included in top ETFsPortfolio Profit Report & Verified Technical Trade Signals - bollywoodhelpline.com
Kodiak Sciences (NASDAQ:KOD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Kodiak Sciences stock hits 52-week high at 26.43 USD - Investing.com
Kodiak Sciences stock hits 52-week high at 26.43 USD By Investing.com - Investing.com Canada
Kodiak Sciences surges after boosted $160 mln equity raise - TradingView — Track All Markets
Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Kodiak Sciences dips after boosted $160 mln equity raise - TradingView — Track All Markets
Kodiak Sciences’ Upsized Equity Raise Could Be A Game Changer For Kodiak Sciences (KOD) - Yahoo Finance
Retina drug developer sells nearly 7M new shares to raise $160M - Stock Titan
Kodiak Sciences prices upsized $160M stock offering at $23.00 per share - MSN
Kodiak Sciences (KOD) Expands Public Offering to Raise $160 Mill - GuruFocus
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):